News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Precision BioSciences Announces Allowance of Five Additional U.S. Patent Applications Related to Engineered Meganucleases


2/23/2012 6:13:21 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office has issued Notices of Allowance for five U.S. Patent Applications: 12/879,428, 13/246,263, 13/245,650, 13/246,355 and 13/246,376 (“the Applications”). The allowed claims relate to a broad set of genome engineering methods and materials. These methods constitute multiple aspects of Precision’s genome engineering technology known as the Directed Nuclease Editor or DNE.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES